Major Health NewsHealth, biotech and life sciences releases

Press Release · Specialised Therapeutics

Specialised Therapeutics and DKSH Partner to Expand Access to Cancer Medicines in Vietnam

Distributed by Major Health News · Originally issued via PR Newswire

SINGAPORE, Nov. 22, 2026 — Singapore-based independent biopharmaceutical company Specialised Therapeutics (ST) and DKSH have signed an exclusive strategic partnership to bring innovative oncology therapies to patients across Vietnam.

According to 2022 GLOBOCAN estimates from the World Health Organization, Vietnam faces a significant and growing cancer burden, with approximately 180,000 new cases and over 120,000 deaths reported annually. The collaboration will directly target two major areas of concern: breast cancer, which is the most frequently diagnosed cancer among Vietnamese women, and lung cancer, a leading cause of cancer-related mortality (GLOBOCAN 2022).

ST currently commercialises oncology products under exclusive licenses covering Southeast Asia, Australia, and New Zealand. The company has successfully secured regulatory approvals in major markets including Australia, New Zealand, Singapore, Thailand, and Malaysia. According to ST, this new partnership in Vietnam strategically extends its regional model into one of Southeast Asia's largest and fastest-growing healthcare markets.

"Vietnam is a priority market for ST, and the right partner makes all the difference," said Carlo Montagner, Chief Executive Officer of Specialised Therapeutics. "DKSH brings deep local market knowledge and expertise, and we look forward to introducing several vital cancer medicines to patients in Vietnam over the next few years."

"We are proud to partner with Specialised Therapeutics to strengthen access to specialty oncology care in Vietnam," said Charaf Kadri, Vice President, Healthcare, DKSH. "At DKSH, our commitment to 'Healthcare for All' drives everything we do. By combining ST's specialty oncology expertise with DKSH's local market knowledge and capabilities, we aim to help improve healthcare outcomes across Vietnam."

Forward-looking statements

This release contains forward-looking statements, including on regulatory submissions, approvals and product launches in Vietnam. Actual outcomes may differ materially and depend on regulatory decisions and other factors outside the companies' control.

Reference

International Agency for Research on Cancer. GLOBOCAN 2022: Vietnam fact sheet. Global Cancer Observatory. Source

SOURCE Specialised Therapeutics

About Specialised Therapeutics

Founded in 2007 and headquartered in Singapore, Specialised Therapeutics (ST) is an independent specialty pharmaceutical company bringing breakthrough therapies and medical technologies to patients across Australia, New Zealand, and Southeast Asia. ST partners with global pharmaceutical, biotech, and diagnostic leaders to commercialise advanced healthcare solutions across a broad range of conditions. Leveraging deep expertise in complex regulatory, reimbursement, and commercial environments, the company is dedicated to addressing unmet medical needs and expanding access to essential treatments for underserved communities. Its growing portfolio, featuring more than 18 global brands, covers oncology, haematology, CNS, neurology, endocrinology, ophthalmology, and dermatology, among other therapeutic areas. Learn more at www.stbiopharma.com. 

About DKSH

For more than 160 years, DKSH has been delivering growth for companies in Asia Pacific, Europe, and North America across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market access support, market insights, marketing and sales, logistics as well as after-sales services, following its purpose of enriching people's lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 35 markets with 26,840 specialists, generating net sales of CHF 11.1 billion in 2025. www.dksh.com